These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 23917652)
1. Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Cruellas MG; Viana Vdos S; Levy-Neto M; Souza FH; Shinjo SK Clinics (Sao Paulo); 2013 Jul; 68(7):909-14. PubMed ID: 23917652 [TBL] [Abstract][Full Text] [Related]
2. The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies. Li S; Ge Y; Yang H; Wang T; Zheng X; Peng Q; Lu X; Wang G Clin Rheumatol; 2019 Aug; 38(8):2171-2179. PubMed ID: 30863950 [TBL] [Abstract][Full Text] [Related]
4. Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. Hengstman GJ; Brouwer R; Egberts WT; Seelig HP; Jongen PJ; van Venrooij WJ; van Engelen BG J Neurol; 2002 Jan; 249(1):69-75. PubMed ID: 11954871 [TBL] [Abstract][Full Text] [Related]
5. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Eloranta ML; Barbasso Helmers S; Ulfgren AK; Rönnblom L; Alm GV; Lundberg IE Arthritis Rheum; 2007 Sep; 56(9):3112-24. PubMed ID: 17763410 [TBL] [Abstract][Full Text] [Related]
6. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis. Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751 [TBL] [Abstract][Full Text] [Related]
7. Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Yamasaki Y; Yamada H; Nozaki T; Akaogi J; Nichols C; Lyons R; Loy AC; Chan EK; Reeves WH; Satoh M Arthritis Rheum; 2006 Jun; 54(6):2004-9. PubMed ID: 16732549 [TBL] [Abstract][Full Text] [Related]
8. Rare myositis-specific autoantibody associations among Hungarian patients with idiopathic inflammatory myopathy. Bodoki L; Nagy-Vincze M; Griger Z; Betteridge Z; Szöllősi L; Jobanputra R; Dankó K Acta Reumatol Port; 2015; 40(4):337-47. PubMed ID: 26922197 [TBL] [Abstract][Full Text] [Related]
9. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. Betteridge Z; Tansley S; Shaddick G; Chinoy H; Cooper RG; New RP; Lilleker JB; Vencovsky J; Chazarain L; Danko K; Nagy-Vincze M; Bodoki L; Dastmalchi M; Ekholm L; Lundberg IE; McHugh N; J Autoimmun; 2019 Jul; 101():48-55. PubMed ID: 30992170 [TBL] [Abstract][Full Text] [Related]
10. Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis. Kryštůfková O; Hulejová H; Mann HF; Pecha O; Půtová I; Ekholm L; Lundberg IE; Vencovský J Arthritis Res Ther; 2018 Jul; 20(1):158. PubMed ID: 30053824 [TBL] [Abstract][Full Text] [Related]
11. [Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases]. Xie MM; Zou RY; Li Y; Liu Y; Chen LL; Liu XQ; Zhao Q; Ding JJ; Chen ZY; Cai HR Zhonghua Jie He He Hu Xi Za Zhi; 2019 Oct; 42(10):765-770. PubMed ID: 31594111 [No Abstract] [Full Text] [Related]
12. [Myositis specific and myositis associated autoantibodies in idiopathic inflammatory myopathies: a serologic study of 46 patients]. Ghirardello A; Zampieri S; Iaccarino L; Tarricone E; Tonello M; Bendo R; Rondinone R; Cozzi F; Doria A Reumatismo; 2005; 57(1):22-8. PubMed ID: 15776143 [TBL] [Abstract][Full Text] [Related]
13. Immunoserological aspects of idiopathic inflammatory muscle disease. Rozman B; Bozic B; Kos-Golja M; Plesivcnik-Novljan M; Kveder T Wien Klin Wochenschr; 2000 Aug; 112(15-16):722-7. PubMed ID: 11020964 [TBL] [Abstract][Full Text] [Related]
17. Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis. Srivastava P; Dwivedi S; Misra R Rheumatol Int; 2016 Jul; 36(7):935-43. PubMed ID: 27193471 [TBL] [Abstract][Full Text] [Related]
18. Clinical significance of myositis-specific autoantibody profiles in Japanese patients with polymyositis/dermatomyositis. Temmoku J; Sato S; Fujita Y; Asano T; Suzuki E; Kanno T; Furuya MY; Matsuoka N; Kobayashi H; Watanabe H; Koga T; Shimizu T; Kawakami A; Migita K Medicine (Baltimore); 2019 May; 98(20):e15578. PubMed ID: 31096460 [TBL] [Abstract][Full Text] [Related]
19. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Krystufková O; Vallerskog T; Helmers SB; Mann H; Putová I; Belácek J; Malmström V; Trollmo C; Vencovsky J; Lundberg IE Ann Rheum Dis; 2009 Jun; 68(6):836-43. PubMed ID: 18628284 [TBL] [Abstract][Full Text] [Related]
20. Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: Relevance for clinical classification: retrospective study of 169 patients. Váncsa A; Gergely L; Ponyi A; Lakos G; Németh J; Szodoray P; Dankó K Joint Bone Spine; 2010 Mar; 77(2):125-30. PubMed ID: 20188618 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]